

**SUPPLEMENTAL MATERIAL: Characterization of Patients With Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment—A US Physician Survey and Retrospective Medical Chart Review**

Reeti Joshi, MD,<sup>1</sup> Dominick Latremouille-Viau, MSc,<sup>2</sup> Mark K. Meiselbach, BS,<sup>3</sup> Jipan Xie, MD, PhD,<sup>4</sup> Yujin Park, PharmD,<sup>5</sup> Prashanth Sunkureddi, MD<sup>6</sup>

<sup>1</sup>Baylor College of Medicine, Houston, TX; <sup>2</sup>Analysis Group, Inc., Montreal, Quebec, Canada; <sup>3</sup>Analysis Group, Inc., Boston, MA; <sup>4</sup>Analysis Group, Inc., Los Angeles, CA; <sup>5</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ; <sup>6</sup>University of Texas Medical Branch, Galveston, TX

**Address correspondence to:**

Reeti Joshi, MD

3560 Delaware, Suite 301


Beaumont, TX 77706

Phone: +1 (409) 363-5675

Fax: +1 (409) 363-5671

Email: [drreetijoshi@gmail.com](mailto:drreetijoshi@gmail.com)

**Figure S1.** Rheumatologist-reported reasons for secukinumab prescription in patients with AS stratified by use of prior biologics (N=78)



AS, ankylosing spondylitis.